{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:56:39Z","timestamp":1774277799835,"version":"3.50.1"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p>Ergotism is the long-term ergot poisoning by ingestion of rye or other grains infected with the fungus<jats:italic>Claviceps purpurea<\/jats:italic>and more recently by excessive intake of ergot drugs. It has either neuropsychiatric or vascular manifestations. In the Middle Ages, the gangrenous poisoning was known as St. Anthony\u2019s fire, after the order of the Monks of St. Anthony who were particularly skilled at treating the condition. In 1917, Prof. Arthur Stoll returned home to Switzerland from Germany, to lead the development of a new pharmaceutical department at Sandoz Chemical Company. Stoll, using the special methods of extraction learned from his work with his mentor Willstetter, started his industrial research work with ergot. He succeeded in isolating, from the ergot of rye, ergotamine as an active principle of an old popular remedy for excessive post-partum bleeding. The success of this discovery occurred in 1918 and was translated into a pharmaceutical product in 1921 under the trade name Gynergen. In subsequent work, Stoll and his team were leaders in identifying the structure of the many other alkaloids and amines produced by<jats:italic>Claviceps purpurea<\/jats:italic>. This was the cultural background and scientific foundation on which bromocriptine was discovered.<\/jats:p>","DOI":"10.1530\/eje-18-0378","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T15:30:14Z","timestamp":1526052614000},"page":"R69-R75","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":23,"title":["ANNIVERSARY REVIEW: 50 years since the discovery of bromocriptine"],"prefix":"10.1093","volume":"179","author":[{"given":"G","family":"Michael Besser","sequence":"first","affiliation":[{"name":"1Medicine, St Bartholomew\u2019s Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald F","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"2Neurology, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael O","family":"Thorner","sequence":"additional","affiliation":[{"name":"3Medicine, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"ref581","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1210\/endo-94-4-1077","article-title":"Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion","volume":"94","year":"1974","journal-title":"Endocrinology"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/0024-3205(77)90231-4","article-title":"Endocrine profile of ergot alkaloids","volume":"21","year":"1977","journal-title":"Life Science"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1210\/jcem-35-5-768","article-title":"The inhibition of prolactin secretion in man by CB-154 (2-Br-alpha-ergocryptine)","volume":"35","year":"1972","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1210\/jcem-53-3-480","article-title":"Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine","volume":"53","year":"1981","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJM197001012820107","article-title":"Similarities between neurologic effects of L-dopa and of apomorphine","volume":"282","year":"1970","journal-title":"New England Journal of Medicine"},{"key":"ref821","first-page":"514","article-title":"Multiple dopamine receptors and their implications in medicine","volume":"5","year":"1992","journal-title":"Current Opinion in Neurology and Neurosurgery"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1056\/NEJM197612162952504","article-title":"Treatment of Parkinson\u2019s disease with bromocriptine","volume":"295","year":"1976","journal-title":"New England Journal of Medicine"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/277093a0","article-title":"Multiple receptors for dopamine","volume":"277","year":"1979","journal-title":"Nature"},{"key":"ref301","first-page":"121","article-title":"Pyrimidyl-piperonyl-piperazine (ET 495) in parkinsonism","year":"1973","journal-title":"Advances in Neurology"},{"key":"ref321","first-page":"473","article-title":"Idiopathic parkinsonism treated with bromocriptine","volume":"2","year":"1975","journal-title":"Lancet"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","year":"2017","journal-title":"JAMA"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"e002279","DOI":"10.1161\/JAHA.112.002279","article-title":"Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects","volume":"1","year":"2012","journal-title":"Journal of the American Heart Association"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/dc11-0064","article-title":"Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes","volume":"34","year":"2011","journal-title":"Diabetes Care"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/BF02147804","article-title":"2-Br-alpha-ergokryptin: influence on fertility and lactation in the rat","volume":"24","year":"1968","journal-title":"Experientia"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/bmj.4.5942.442","article-title":"Bromocriptine in Parkinsonism","volume":"4","year":"1974","journal-title":"BMJ"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/0024-3205(77)90231-4","article-title":"Endocrine profile of ergot alkaloids","volume":"21","year":"1977","journal-title":"Life Science"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1530\/acta.0.0230151","article-title":"Progesterone reversal of ergotoxine induced suppression of early \u2013 pre-implantation \u2013 pregnancy","volume":"23","year":"1956","journal-title":"Acta Endocrinologica"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/jcem-35-6-941","article-title":"Inhibitory effect of L-Dopa on GH release in acromegalic patients","volume":"35","year":"1972","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref851","first-page":"44","article-title":"Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson\u2019s disease","volume":"1","year":"1981","journal-title":"Lancet"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: a consensus on the medical treatment of acromegaly","volume":"10","year":"2014","journal-title":"Nature Reviews Endocrinology"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/acta.0.0270099","article-title":"Maintenance of gestation of ergotoxine-treated pregnant rats by exogenous prolactin","volume":"27","year":"1958","journal-title":"Acta Endocrinologica"},{"key":"ref761","first-page":"121","article-title":"Pyrimidyl-piperonyl-piperazine (ET 495) in parkinsonism","year":"1973","journal-title":"Advances in Neurology"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/bmj.4.5942.442","article-title":"Bromocriptine in Parkinsonism","volume":"4","year":"1974","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1152\/ajplegacy.1954.179.2.301","article-title":"Ergotoxine inhibition of deciduoma formation and its reversal by progesterone","volume":"179","year":"1954","journal-title":"American Journal of Physiology"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/jnnp.39.2.184","article-title":"Bromocriptine treatment in Parkinson\u2019s disease","volume":"39","year":"1976","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"ref361","first-page":"514","article-title":"Multiple dopamine receptors and their implications in medicine","volume":"5","year":"1992","journal-title":"Current Opinion in Neurology and Neurosurgery"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1530\/acta.0.0560027","article-title":"Effect of ergocornine on ovarian synthesis of progesterone and 20 alpha-hydroxy-pregn-4-en-3-one in the pseudopregnant rat","volume":"56","year":"1967","journal-title":"Acta Endocrinologica"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.2042-7158.1973.tb10037.x","article-title":"Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons","volume":"25","year":"1973","journal-title":"Journal of Pharmacy and Pharmacology"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1210\/jcem-51-3-438","article-title":"Rapid regression of pituitary prolactinomas during bromocriptine treatment","volume":"51","year":"1980","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref781","first-page":"473","article-title":"Idiopathic parkinsonism treated with bromocriptine","volume":"2","year":"1975","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/acta.0.0270099","article-title":"Maintenance of gestation of ergotoxine-treated pregnant rats by exogenous prolactin","volume":"27","year":"1958","journal-title":"Acta Endocrinologica"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/bmj.1.6065.875","article-title":"Long-term treatment of acromegaly with bromocriptine","volume":"1","year":"1977","journal-title":"BMJ"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/jns.1984.60.1.0001","article-title":"Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors","volume":"60","year":"1984","journal-title":"Journal of Neurosurgery"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/dc11-0064","article-title":"Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes","volume":"34","year":"2011","journal-title":"Diabetes Care"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM196702162760703","article-title":"Aromatic amino acids and modification of parkinsonism","volume":"276","year":"1967","journal-title":"New England Journal of Medicine"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/bmj.1.5953.299","article-title":"Bromocriptine treatment of acromegaly","volume":"1","year":"1975","journal-title":"BMJ"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1126\/science.170.3959.745","article-title":"Prolactin: evidence that it is separate from growth hormone in human blood","volume":"170","year":"1970","journal-title":"Science"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1210\/endo-102-6-1895","article-title":"Dopamine levels in hypophysial stalk blood in the rat are sufficient to inhibit prolactin secretion in vivo","volume":"102","year":"1978","journal-title":"Endocrinology"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2265.1982.tb01602.x","article-title":"Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly","volume":"17","year":"1982","journal-title":"Clinical Endocrinology"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1212\/WNL.0b013e318232ab4c","article-title":"Does levodopa accelerate the pathologic process in Parkinson disease brain?","volume":"77","year":"2011","journal-title":"Neurology"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1530\/acta.0.0560027","article-title":"Effect of ergocornine on ovarian synthesis of progesterone and 20 alpha-hydroxy-pregn-4-en-3-one in the pseudopregnant rat","volume":"56","year":"1967","journal-title":"Acta Endocrinologica"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2265.1982.tb01602.x","article-title":"Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly","volume":"17","year":"1982","journal-title":"Clinical Endocrinology"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM196702162760703","article-title":"Aromatic amino acids and modification of parkinsonism","volume":"276","year":"1967","journal-title":"New England Journal of Medicine"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1212\/01.WNL.0000152880.77812.5B","article-title":"\u2018Levodopa phobia\u2019: a new iatrogenic cause of disability in Parkinson disease","volume":"64","year":"2005","journal-title":"Neurology"},{"key":"ref871","volume-title":"Bromocriptine: A Clinical and Pharmacological Review","year":"1980"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/bmj.3.5828.669","article-title":"Galactorrhoea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine","volume":"3","year":"1972","journal-title":"BMJ"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/bmj.1.5953.299","article-title":"Bromocriptine treatment of acromegaly","volume":"1","year":"1975","journal-title":"BMJ"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"e002279","DOI":"10.1161\/JAHA.112.002279","article-title":"Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects","volume":"1","year":"2012","journal-title":"Journal of the American Heart Association"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/BF02147804","article-title":"2-Br-alpha-ergokryptin: influence on fertility and lactation in the rat","volume":"24","year":"1968","journal-title":"Experientia"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/jns.1984.60.1.0001","article-title":"Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors","volume":"60","year":"1984","journal-title":"Journal of Neurosurgery"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0021-9258(19)45475-6","article-title":"Purification of human prolactin","volume":"247","year":"1972","journal-title":"Journal of Biological Chemistry"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1126\/science.170.3959.745","article-title":"Prolactin: evidence that it is separate from growth hormone in human blood","volume":"170","year":"1970","journal-title":"Science"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/bmj.1.6065.875","article-title":"Long-term treatment of acromegaly with bromocriptine","volume":"1","year":"1977","journal-title":"BMJ"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/bmj.3.5768.225","article-title":"Plasma prolactin activity in inappropriate lactation","volume":"3","year":"1971","journal-title":"BMJ"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1210\/endo-102-6-1895","article-title":"Dopamine levels in hypophysial stalk blood in the rat are sufficient to inhibit prolactin secretion in vivo","volume":"102","year":"1978","journal-title":"Endocrinology"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJM197612162952511","article-title":"Developments in the treatment of parkinsonism","volume":"295","year":"1976","journal-title":"New England Journal of Medicine"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","year":"2017","journal-title":"JAMA"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1210\/jcem-53-3-480","article-title":"Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine","volume":"53","year":"1981","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1210\/jcem-38-5-910","article-title":"Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration","volume":"38","year":"1974","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1212\/WNL.0b013e318232ab4c","article-title":"Does levodopa accelerate the pathologic process in Parkinson disease brain?","volume":"77","year":"2011","journal-title":"Neurology"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/jnnp.39.2.184","article-title":"Bromocriptine treatment in Parkinson\u2019s disease","volume":"39","year":"1976","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1172\/JCI106643","article-title":"Human prolactin: measurement in plasma by in vitro bioassay","volume":"50","year":"1971","journal-title":"Journal of Clinical Investigation"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: a consensus on the medical treatment of acromegaly","volume":"10","year":"2014","journal-title":"Nature Reviews Endocrinology"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.2.5916.419","article-title":"Long-term treatment of galactorrhoea and hypogonadism with bromocriptine","volume":"2","year":"1974","journal-title":"BMJ"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/277093a0","article-title":"Multiple receptors for dopamine","volume":"277","year":"1979","journal-title":"Nature"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/bmj.3.5768.225","article-title":"Plasma prolactin activity in inappropriate lactation","volume":"3","year":"1971","journal-title":"BMJ"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1172\/JCI106643","article-title":"Human prolactin: measurement in plasma by in vitro bioassay","volume":"50","year":"1971","journal-title":"Journal of Clinical Investigation"},{"key":"ref391","first-page":"44","article-title":"Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson\u2019s disease","volume":"1","year":"1981","journal-title":"Lancet"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17446651.2016.1131119","article-title":"Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary","volume":"11","year":"2016","journal-title":"Expert Review of Endocrinology and Metabolism"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17446651.2016.1131119","article-title":"Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary","volume":"11","year":"2016","journal-title":"Expert Review of Endocrinology and Metabolism"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/jcem-35-6-941","article-title":"Inhibitory effect of L-Dopa on GH release in acromegalic patients","volume":"35","year":"1972","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/archinte.1988.00380100089019","article-title":"Pleuropulmonary disease during bromocriptine treatment of Parkinson\u2019s disease","volume":"148","year":"1988","journal-title":"Archives of Internal Medicine"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0021-9258(19)45475-6","article-title":"Purification of human prolactin","volume":"247","year":"1972","journal-title":"Journal of Biological Chemistry"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.2042-7158.1973.tb10037.x","article-title":"Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons","volume":"25","year":"1973","journal-title":"Journal of Pharmacy and Pharmacology"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJM197612162952511","article-title":"Developments in the treatment of parkinsonism","volume":"295","year":"1976","journal-title":"New England Journal of Medicine"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJM197001012820107","article-title":"Similarities between neurologic effects of L-dopa and of apomorphine","volume":"282","year":"1970","journal-title":"New England Journal of Medicine"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1210\/jcem-38-5-910","article-title":"Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration","volume":"38","year":"1974","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1152\/ajplegacy.1954.179.2.301","article-title":"Ergotoxine inhibition of deciduoma formation and its reversal by progesterone","volume":"179","year":"1954","journal-title":"American Journal of Physiology"},{"key":"ref561","first-page":"884","article-title":"Prolactin inhibition and suppression of puerperal lactation by a Br-erocryptine (CB 154). A comparison with estrogen","volume":"41","year":"1973","journal-title":"Obstetrics and Gynecology"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1210\/jcem-35-5-768","article-title":"The inhibition of prolactin secretion in man by CB-154 (2-Br-alpha-ergocryptine)","volume":"35","year":"1972","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1210\/jcem-51-3-438","article-title":"Rapid regression of pituitary prolactinomas during bromocriptine treatment","volume":"51","year":"1980","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/archinte.1988.00380100089019","article-title":"Pleuropulmonary disease during bromocriptine treatment of Parkinson\u2019s disease","volume":"148","year":"1988","journal-title":"Archives of Internal Medicine"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1056\/NEJM197612162952504","article-title":"Treatment of Parkinson\u2019s disease with bromocriptine","volume":"295","year":"1976","journal-title":"New England Journal of Medicine"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1212\/01.WNL.0000152880.77812.5B","article-title":"\u2018Levodopa phobia\u2019: a new iatrogenic cause of disability in Parkinson disease","volume":"64","year":"2005","journal-title":"Neurology"},{"key":"ref101","first-page":"884","article-title":"Prolactin inhibition and suppression of puerperal lactation by a Br-erocryptine (CB 154). A comparison with estrogen","volume":"41","year":"1973","journal-title":"Obstetrics and Gynecology"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.2.5916.419","article-title":"Long-term treatment of galactorrhoea and hypogonadism with bromocriptine","volume":"2","year":"1974","journal-title":"BMJ"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/bmj.3.5828.669","article-title":"Galactorrhoea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine","volume":"3","year":"1972","journal-title":"BMJ"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1758-5996-6-104","article-title":"Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats","volume":"6","year":"2014","journal-title":"Diabetology and Metabolic Syndrome"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1530\/acta.0.0230151","article-title":"Progesterone reversal of ergotoxine induced suppression of early \u2013 pre-implantation \u2013 pregnancy","volume":"23","year":"1956","journal-title":"Acta Endocrinologica"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1758-5996-6-104","article-title":"Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats","volume":"6","year":"2014","journal-title":"Diabetology and Metabolic Syndrome"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1210\/endo-94-4-1077","article-title":"Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion","volume":"94","year":"1974","journal-title":"Endocrinology"},{"key":"ref411","volume-title":"Bromocriptine: A Clinical and Pharmacological Review","year":"1980"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/179\/2\/EJE-18-0378.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1530\/EJE-18-0378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T18:16:57Z","timestamp":1720289817000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/179\/2\/R69\/6655383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":92,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/eje-18-0378","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}